Figure 1. Flowchart of eligible and ineligible participants. The flowchart shows the selection of eligible and ineligible participants. MTX-naive patients were those who had no history of MTX prescriptions before the disaster, while MTX users were those who had a history of MTX prescriptions after the disaster. MTX: methotrexate.
Figure 2. Time trend of adjusted OR of disaster victims for prescription of total MTX before and after the disaster. This analysis includes all eligible participants. This plot displays the adjusted OR for disaster victims regarding the association with total MTX prescriptions before and after the disaster. Pre-disaster users were included to evaluate trends prior to the disaster. The p-value for interaction indicates the association between the time variable (pre- or post-disaster) and disaster-affected status. MTX: methotrexate; OR: odds ratio.
Figure 3. Kaplan-Meier failure curves for the participants newly prescribed with MTX. This analysis was performed on the MTX-naive group. The Kaplan-Meier curve illustrates the incidence of new MTX prescriptions within a span of 12 months after the disaster for victims and non-victims. MTX: methotrexate.
Figure 4. Kaplan-Meier failure curves for the participants newly prescribed with any other antirheumatic drugs. This analysis was performed on the MTX-user group. The Kaplan-Meier curve depicts the incidence of new other antirheumatic drug prescriptions (csDMARDs, bDMARDs, and glucocorticoids) among MTX-treated participants within a span of 12 months after the disaster among victims and non-victims. bDMARD: biological disease-modifying antirheumatic drugs; csDMARD: conventional synthetic disease-modifying antirheumatic drugs; MTX: methotrexate.
